Synbio International Inc

Synbio International Inc. aims to improve health & wellness by developing AI-based medical technology and meeting the growing demand for nutraceutical products.

[Synbio International Inc @SYINofficial]

The CEO of FacialDx, Doug Benoit and I in Australia this week. We met with the team at Resonance Health to begin planning the mental health clinical trial. Exciting progress as we move toward validation. #SYIN #Facialdx #mentalhealth #healthtech

[Synbio International Inc @SYINofficial]

Great to see the interest in what is an important development in mental health. https://t.co/K68pxEmlCr

[Synbio International Inc @SYINofficial]

https://t.co/c2cgAk90ox

[Synbio International Inc @SYINofficial]

@elonmuskperry Game over

[Synbio International Inc @SYINofficial]

Working on the Statement of Work, trial timeline, and projected costs of the trial. The time is tight for an objective, rapid tool to help identify mental health conditions — we’re seeing meaningful progress now.
#SYIN #MentalHealth #AI

[Synbio International Inc @SYINofficial]

https://t.co/3qVmf1sxGu

[Synbio International Inc @SYINofficial]

@elonmuskTehh7 8960

[Synbio International Inc @SYINofficial]

@elonnewsupdatex Hope

[Synbio International Inc @SYINofficial]

@elonnewsupdatex Open your eyes

[Synbio International Inc @SYINofficial]

@Wisdom_HQ Hope

[Synbio International Inc @SYINofficial]

Synbio has signed an agreement with a leading clinical research organization to conduct a clinical trial evaluating a proactive, non-invasive, AI-powered facial analysis test for PTSD and depression.  Mental health deserves better tools - and a new approach is taking shape. #SYIN

[Synbio International Inc @SYINofficial]

I was delighted to recently host a Director from our Australian CRO for the upcoming feasibility trial. Conducting the trial in Australia offers major Forex cost & tax advantages + a CRO with deep expertise and a proven FDA track record. #SYIN #MedTech #AIHealth #ClinicalTrials

[Synbio International Inc @SYINofficial]

A major step forward. Great to have Dr Vatakis on board.

https://t.co/nRr1TuTosR

$SYIN

[Synbio International Inc @SYINofficial]

Things are moving nicely. New early-revenue opportunities have been identified with FacialDx, complementing the facial-analysis medtech. And stay tuned for more soon on a great development at FacialDx and another SYIN key executive appointment. 🚀 $SYIN #MedTech #AI #MentalHealth

[Synbio International Inc @SYINofficial]

Last week in NYC I caught up with my good friend Doug Benoit, CEO of FacialDx. We discussed the enormous potential of facial analysis & finalized a press release for tomorrow re a closer tie between our companies, enabling $SYIN to share in the ownership of the facial-analysis IP

[Synbio International Inc @SYINofficial]

Really excited to have announced today the first of our board appointments. Ms Desiree Cain as Synbio’s CFO. Great addition to the executive team and I’m very much looking forward to working with her. This marks the beginning of Synbio’s next phase of growth. $SYIN

[Synbio International Inc @SYINofficial]

Great to welcome Doug Benoit CEO of FacialDx to NYC. We explored major opportunities in facial analysis, met with an investment bank about future funding and strengthened collaboration agreements. Press releases coming soon as we advance validation & commercialisation initiatives

[Synbio International Inc @SYINofficial]

We know that shareholders are eager for updates. Rest assured we are making good progress whilst going through the necessary legal & corporate checks and balances. Your patience is very much appreciated. We look forward to the rollout & sharing all the details with you very soon

[Synbio International Inc @SYINofficial]

I know our shareholders are eager for updates. Rest assured we are making good progress whilst going through the legal checks and balances. You patients is very much appreciated. We look forward to sharing the details very soon.

[Synbio International Inc @SYINofficial]

We’re strengthening our agreement with FacialDx by including a cross shareholding arrangement giving us a stake the facial analysis IP. Importantly it aligns our shared vision and reinforces our partnership for the long term. Details will follow on completion of legal review.